edoc

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis

van den Elskamp, I. J. and Boden, B. and Dattola, V. and Knol, D. L. and Filippi, M. and Kappos, L. and Fazekas, F. and Wagner, K. and Pohl, C. and Sandbrink, R. and Polman, C. H. and Uitdehaag, B. M. J. and Barkhof, F.. (2010) Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology, Vol. 52, H. 10. pp. 875-881.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006321

Downloads: Statistics Overview

Abstract

Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents. In this study, we evaluate the rate of cerebral atrophy in a 6-month period, investigate the predictive and explanatory value of other magnetic resonance imaging (MRI) measures in relation to cerebral atrophy, and determine sample sizes for future short-term clinical trials using cerebral atrophy as primary outcome measure.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Springer
ISSN:0028-3940
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:26 Apr 2013 07:02
Deposited On:26 Apr 2013 06:54

Repository Staff Only: item control page